Interference of labetalol metabolites in the determination of plasma catecholamines by HPLC with electrochemical detection.
The alpha and beta adrenoceptor blocking drug labetalol is a potent antihypertensive agent in widespread clinical use. Its interference in the classical chemical estimations of urinary catecholamines and their metabolites has been the subject of several reports. Factitiously raised values have been noted in both the fluorimetric catecholamine assay, and the standard spectrophotometric procedure for total (free and conjugated) metadrenalines. To avoid such drug interference, modification of these methods is required in the estimation of catecholamines and their o-methylated metabolites. Alternatively, VMA estimations or plasma/urinary catecholamine measurements by radioenzymatic assay may be used in patients on labetalol. Although high performance liquid chromatography coupled with electrochemical detection (HPLC-ECD) methods for estimation of plasma catecholamines are now in widespread use, the interference of labetalol in this method has not been reported. We now report that significant direct interference of labetalol in the HPLC-ECD assay does indeed occur, and can yield spuriously raised adrenaline levels.
D000537:Aluminum Oxide; D002395:Catecholamines / Q000097:blood*; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D004563:Electrochemistry; D005189:False Positive Reactions; D006801:Humans; D007741:Labetalol / Q000378:metabolism*
D002395:Catecholamines; D000537:Aluminum Oxide; D007741:Labetalol